Simple Summary Urothelial cell carcinoma (UCC) is the ninth most common cancer
worldwide and in the US the fourth most common cancer, with~ 82,000 new cases (~ 62,000 …

Bladder cancer is the sixth most common cancer in the US and most tumors have urothelial
(transitional cell) histology. Platinum-based chemotherapy has long been the standard of …

Introduction: Urothelial carcinoma is one of the most common cancers in the western world
and, until recently, had limited therapeutic options. The contemporary advancement of …

Immune checkpoint inhibitors have revolutionized the field of oncology, providing a novel
mechanism for anticancer therapy. Programmed death 1--targeting antibodies …

Simple Summary Urothelial carcinoma is an aggressive cancer with a high risk of metastatic
progression. Chemotherapy plays a key role in the management of metastatic urothelial …

Objectives To compare clinical outcomes between patients with locally advanced
(unresectable) or metastatic urothelial carcinoma (aUC) in the upper and lower urinary tract …

Clinical trials revealed significant antitumor activity for immune checkpoint inhibitors (ICI) in
metastatic urothelial carcinoma (mUC). Due to their strict eligibility criteria, clinical trials …

Urothelial carcinoma (UC), originating in the bladder or upper urinary tract, is the most
common histological type of cancer. Currently, platinum-based cytotoxic chemotherapy is …

Metastatic urothelial cancer is an aggressive disease associated with a poor prognosis. In
the first-line setting, platinum-based chemotherapy is the standard of care but resistance …

Advancements in the understanding of tumor immunology in urothelial carcinoma (UC) have
led to US Food and Drug Administration (FDA) approval of five novel anti-programmed cell …